Travere Therapeutics (TVTX) CFO reports 20,000-share 10b5-1 sale and option exercise

Q: What insider transaction did Travere Therapeutics (TVTX) report in this Form 4?

The Chief Financial Officer of Travere Therapeutics, Inc. reported exercising an employee stock option for 20,000 shares of common stock at an exercise price of $16.23 per share and selling 20,000 shares of common stock on 12/01/2025 .

Q: At what prices did the Travere Therapeutics (TVTX) CFO sell shares?

The weighted average sale price was $35.0101 per share, with individual sale prices ranging between $34.64 and $35.41 . Full details by price level are available upon request from the company or the SEC staff.

Q: How many Travere Therapeutics (TVTX) shares does the CFO own after this transaction?

After the reported option exercise and sale on 12/01/2025 , the Chief Financial Officer directly beneficially owned 92,083 shares of Travere Therapeutics common stock.

Q: What was the original grant and expiration date of the Travere Therapeutics (TVTX) stock option?

The employee stock option exercised for 20,000 shares was granted to the Reporting Person on May 19, 2016 , with an expiration date of May 19, 2026 . The filing notes that this stock option is fully vested and exercisable.

Q: What role does the reporting person hold at Travere Therapeutics (TVTX)?

The reporting person is identified as an officer of Travere Therapeutics, Inc., serving in the position of Chief Financial Officer .

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Travere Therapeutics, Inc. reported an insider stock transaction by its Chief Financial Officer on 12/01/2025. The CFO exercised an employee stock option to acquire 20,000 shares of common stock at an exercise price of $16.23 per share, then sold 20,000 shares of common stock the same day. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025 and related to an option grant originally made on May 19, 2016.

The weighted average sale price was $35.0101 per share, with individual sale prices ranging from $34.64 to $35.41. Following these transactions, the CFO directly beneficially owned 92,083 shares of Travere Therapeutics common stock.

Insider Trade Summary

Exercise and Sale: 20,000 shares ($376K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Cline Christopher R.

Role CHIEF FINANCIAL OFFICER

Sold 20,000 shs ($700K)

Approx. gross sale proceeds $700K

Approx. exercise cost $325K

Approx. pre-tax spread $376K

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy)	20,000	$0.00	$0.00
Exercise	Common Stock	20,000	$16.23	$325K
Sale	Common Stock	20,000	$35.0101	$700K

Holdings After Transaction: Employee stock option (right to buy) — 0 shares (Direct); Common Stock — 92,083 shares (Direct)

Footnotes (3)

F1. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016, with an expiration date of May 19, 2026.
F2. The weighted average sale price for the transaction reported was $35.0101, and the range of prices were between $34.64 and $35.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3. The stock option is fully vested and exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 12/03/2025 - 04:30 PM

FAQ

What insider transaction did Travere Therapeutics (TVTX) report in this Form 4?

The Chief Financial Officer of Travere Therapeutics, Inc. reported exercising an employee stock option for 20,000 shares of common stock at an exercise price of $16.23 per share and selling 20,000 shares of common stock on 12/01/2025.

At what prices did the Travere Therapeutics (TVTX) CFO sell shares?

The weighted average sale price was $35.0101 per share, with individual sale prices ranging between $34.64 and $35.41. Full details by price level are available upon request from the company or the SEC staff.

Was the Travere Therapeutics (TVTX) insider sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the sale was made pursuant to a written plan adopted on May 28, 2025 that meets the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

How many Travere Therapeutics (TVTX) shares does the CFO own after this transaction?

After the reported option exercise and sale on 12/01/2025, the Chief Financial Officer directly beneficially owned 92,083 shares of Travere Therapeutics common stock.

What was the original grant and expiration date of the Travere Therapeutics (TVTX) stock option?

The employee stock option exercised for 20,000 shares was granted to the Reporting Person on May 19, 2016, with an expiration date of May 19, 2026. The filing notes that this stock option is fully vested and exercisable.

What role does the reporting person hold at Travere Therapeutics (TVTX)?

The reporting person is identified as an officer of Travere Therapeutics, Inc., serving in the position of Chief Financial Officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cline Christopher R.

(Last)

(First)

(Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/01/2025		M		20,000	A	$16.23	112,083	D
Common Stock	12/01/2025		S⁽¹⁾		20,000	D	$35.0101⁽²⁾	92,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee stock option (right to buy)	$16.23	12/01/2025		M			20,000	⁽³⁾	05/19/2026	Common Stock	20,000	$0	0	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016, with an expiration date of May 19, 2026.

2. The weighted average sale price for the transaction reported was $35.0101, and the range of prices were between $34.64 and $35.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR